Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

131.04
+0.39000.30%
Post-market: 131.040.00000.00%19:43 EDT
Volume:1.11M
Turnover:145.29M
Market Cap:19.20B
PE:12.95
High:131.58
Open:131.49
Low:128.83
Close:130.65
Loading ...

Biogen Is Maintained at Buy by Goldman Sachs

Dow Jones
·
23 Apr

Goldman Sachs Adjusts Price Target on Biogen to $197 From $219, Maintains Buy Rating

MT Newswires Live
·
23 Apr

Biogen Is Maintained at Outperform by RBC Capital

Dow Jones
·
22 Apr

RBC Lifts Price Target on Biogen to $225 From $221, Keeps Outperform Rating

MT Newswires Live
·
22 Apr

U.S. RESEARCH ROUNDUP-Amazon, Comerica, United Airlines

Reuters
·
22 Apr

Biogen Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
22 Apr

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
18 Apr

Biogen Unlikely to Receive Boost from Leqembi Approval in EU -- Market Talk

Dow Jones
·
17 Apr

Drug to Treat Underlying Causes of Alzheimer's Gets EU Marketing Approval

Dow Jones
·
16 Apr

Biogen Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
16 Apr

Biogen reports EC grants marketing authorization for Leqembi

TIPRANKS
·
16 Apr

Biogen, Eisai's Alzheimer's Drug Leqembi Approved in EU

MT Newswires Live
·
16 Apr

EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease

Reuters
·
15 Apr

Goldman Sachs Adjusts Biogen's Price Target to $219 From $245, Keeps Buy Rating

MT Newswires Live
·
15 Apr

Biogen Inc. Stock Climbs 3.6%, Outperforms Competitors

Dow Jones
·
15 Apr

BUZZ-Potential EU approval for Biogen's Alzheimer's drug underway; shares rise

Reuters
·
14 Apr

Biogen (BIIB) Receives a Hold from Jefferies

TIPRANKS
·
14 Apr

Biogen - Final Process for Ec Decision on Lecanemab’s Marketing Authorisation Application Underway

THOMSON REUTERS
·
14 Apr

Goldman Sachs Cuts Price Target on Biogen to $219 From $245

MT Newswires Live
·
14 Apr

Pharma Tariffs Are Coming. Investors Underestimate the Risk. -- Barrons.com

Dow Jones
·
12 Apr